Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Weekly low-dose combo aims to tame bone marrow cancers with fewer side effects

NCT ID NCT05184842

First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 24 times

Summary

This study tests a new, lower-dose weekly schedule of two approved drugs (decitabine and venetoclax) for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler approach can control the disease while causing fewer treatment delays or interruptions. About 91 adults who are likely to respond to this type of therapy will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-••••

  • University of California Davis Health (UC Davis Health)

    RECRUITING

    Sacramento, California, 95817, United States

  • White Plains Hospital

    RECRUITING

    White Plains, New York, 10601, United States

Conditions

Explore the condition pages connected to this study.